Spectral Medical Inc. provided an update on the Company's Tigris trial, a Phase 3 follow-on study evaluating the use of Polymyxin B Hemoperfusion ("PMX") in a randomized controlled trial of adults treated for endotoxemia and septic shock. Enrollment: Robust enrollment activity continuing throughout the first half of 2024: 116 patients enrolled at end of June 2024; Record monthly enrollment with nine patients enrolled in June; Thirty-five patients enrolled in 2024 so far - represents the most robust enrollment rates since the start of the Tigris study; With 34 patients to full enrollment, the Company is entering the final push to fully enroll and finish the Tigris trial Trial Sites: Currently 23 clinical sites; Recently onboarded the Thomas Jefferson University; an experienced, high-quality site from the EUPHRATES trial; Spectral clinical team focused on trial site management activities to ensure that Tigris sites have the support and resources to enroll patients as efficiently as possible.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
0.495 CAD | +1.02% | +5.32% | +16.47% |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+16.47% | 102M | |
+56.89% | 823B | |
+39.52% | 627B | |
-6.55% | 353B | |
+15.99% | 320B | |
+7.92% | 295B | |
+13.74% | 239B | |
+13.83% | 220B | |
-0.49% | 219B | |
+7.94% | 167B |
- Stock Market
- Equities
- EDT Stock
- News Spectral Medical Inc.
- Spectral Medical Inc. Provides June Tigris Trial Update